Search Videos by Topic or Participant
Browse by Series:

Newly Diagnosed mCRC Treatment Goals

Insights From: Marwan G. Fakih, MD,City of Hope
Published: Thursday, Apr 16, 2015
For High-Definition, Click
The frontline treatment of patients with metastatic colorectal cancer (mCRC) is largely dependent on upfront RAS mutation status, explains Marwan G. Fakih, MD. Traditionally, KRAS testing was utilized in this space; however, recent evidence suggests that RAS could be more predictive of response.
 
A biomarker analysis of the phase III PRIME study that was published in the New England Journal of Medicine showed that narrowing down treatment with panitumumab to patients with only RAS wild-type mutations resulted in an improvement in overall survival (OS) of 5.8 months.
 
The median OS with panitumumab was 26.0 months compared with 20.2 months with FOLFOX alone in patients with wild-type RAS (HR = 0.78; P = .04). Patients with RAS mutations had a 3.6-month worse median OS with panitumumab compared with FOLFOX alone (15.6 vs 19.2 months; HR = 1.25; P = .04).
 
In addition to expanded RAS testing, Fakih typically orders BRAF testing, since these mutations are associated with distinct clinical characteristics and worse prognosis. Other important considerations include whether the intent of therapy is curative or palliative, age, performance status, and pattern of metastatic disease.
Slider Left
Slider Right
For High-Definition, Click
The frontline treatment of patients with metastatic colorectal cancer (mCRC) is largely dependent on upfront RAS mutation status, explains Marwan G. Fakih, MD. Traditionally, KRAS testing was utilized in this space; however, recent evidence suggests that RAS could be more predictive of response.
 
A biomarker analysis of the phase III PRIME study that was published in the New England Journal of Medicine showed that narrowing down treatment with panitumumab to patients with only RAS wild-type mutations resulted in an improvement in overall survival (OS) of 5.8 months.
 
The median OS with panitumumab was 26.0 months compared with 20.2 months with FOLFOX alone in patients with wild-type RAS (HR = 0.78; P = .04). Patients with RAS mutations had a 3.6-month worse median OS with panitumumab compared with FOLFOX alone (15.6 vs 19.2 months; HR = 1.25; P = .04).
 
In addition to expanded RAS testing, Fakih typically orders BRAF testing, since these mutations are associated with distinct clinical characteristics and worse prognosis. Other important considerations include whether the intent of therapy is curative or palliative, age, performance status, and pattern of metastatic disease.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x